Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Herceptin (Trastuzumab) in Combination Therapy in Patients With Metastatic Breast Cancer

Status: Completed

Protocol number: M77003

Sponsor: F Hoffman-La Roche Ltd

Company division: Pharmaceutical

Brief summary: This study will assess the cardiac safety and the efficacy of intravenous Herceptin in combination with epirubicin and cyclophosphamide (E/C), compared to E/C alone, as first-line therapy in anthracycline-naive patients with metastatic breast cancer. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals. Target sample size is 180.

Study phase: II

Study type: Interventional; Treatment; Non-Randomized; Open Label; Uncontrolled; Parallel; Safety/Efficacy study

Condition: Breast Cancer

Intervention type: Drug

Intervention name: trastuzumab[Herceptin]

Primary outcome: 1. Occurrence of cardiotoxicity

Key secondary outcomes: 1. Efficacy: Overall response rate and time to progression. Safety: acute coronary syndrome, acute myocardial infarction, severe rhythm disturbances, and asymptomatic decreases in left ventricular ejection fraction

Inclusion criteria:

  • female patients >18 years of age;
  • histologically confirmed breast cancer;
  • clinically or radiologically confirmed recurrent or metastatic breast cancer;
  • HER2 overexpression (for patients included in the Herceptin arms).

Exclusion criteria:

  • any previous anti-HER treatment or anthracycline-containing chemotherapy;
  • previous cytotoxic chemotherapy for metastasis;
  • serious cardiac illness (specified in the protocol).

Gender: Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Trial registration date: 06/24/2005

Date last updated: 9/29/2008


Link to trial result

This trial was conducted at the following locations:

Croatia

  • Zagreb

France

  • Caen

Germany

  • Berlin
  • Bonn
  • Göttingen
  • Hamburg
  • Hannover
  • Jena
  • Karlsruhe
  • Kiel
  • Magdeburg
  • München
  • Münster
  • Trier
  • Tübingen
  • Ulm
  • Wiesbaden

Hungary

  • Kistarcsa
  • Pecs

Russian Federation

  • Ekaterinburg
  • Kazan
  • Moscow
  • St Petersburg

United Kingdom

  • Epping
  • Newcastle upon Tyne
  • Truro

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply